Table 3.

Pre-exposure prophylactic treatment schedules for the different SARS-CoV-2-neutralizing monoclonal antibodies in our patients, status of marketing authorization for pre-exposure prophylactic treatment in the EU, and neutralizing capacity against the SARS-CoV-2 Omicron strain.

SARS-CoV-2-neutralizing antibodies	Casirivimab/Imdevimab	Sotrovimab	Tixagevimab/Cilgavimab
Route of application	Single intravenous infusion or subcutaneous injection	Intravenous infusion	Two separate intramuscular injections
Dose	First treatment 600 mg/600 mg Repeat treatment 300 mg/300 mg	500 mg	150 mg/150 mg
Treatment interval	Every four weeks	Every eight weeks	Every six months
Approved for pre-exposure prophylaxis in EU	+	–	+
Neutralizing capacity against SARS-CoV-2 Omicron strain	None or insufficient	Fully or largely retained	Retained, but reduced

+, approved for pre-exposure prophylaxis in EU; -, not approved for pre-exposure prophylaxis in EU.